FDA Approves Jadenu Tablets For Treating Chronic Iron Overload

Novartis AG March 30 announced that the Food and Drug Administration has approved Jadenu (deferasirox) tablets for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.

The FDA also approved Jadenu for the treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older.

Jadenu, a new oral formulation of Exjade tablets for oral suspension, is the only once-daily oral iron chelator that can be swallowed whole, the company said. Many patients with sickle cell disease, thalassemia or myelodysplastic syndromes need repeated blood transfusions ...